Supadopa-TR
Generic Name
Fictional Dopamine Receptor Agonist Modified Release Capsule
Manufacturer
Innovate Pharma Solutions Ltd.
Country
Global
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| supadopa tr 2375 mg capsule | ৳ 30.00 | ৳ 180.00 |
Description
Overview of the medicine
Supadopa-TR 23.75 mg capsule is a modified-release medication designed to treat symptoms of Parkinson's disease by acting on dopamine receptors in the brain. Its extended-release formulation provides sustained therapeutic levels.
Uses & Indications
Dosage
Adults
Initial dose 23.75 mg once daily, preferably with food. May be increased gradually to a maximum of 95 mg daily based on response.
Elderly
Same as adults, but dose titration should be done cautiously due to potential for increased sensitivity.
Renal_impairment
Mild to moderate impairment: No initial dose adjustment; severe impairment: Not recommended, or dose reduction by 50% under strict medical supervision.
How to Take
Take orally once daily, in the morning, with or without food. Swallow the capsule whole; do not chew, crush, or divide.
Mechanism of Action
Functions as a selective agonist for dopamine D2 and D3 receptors. It mimics the effects of dopamine in the brain, helping to improve motor symptoms associated with Parkinson's disease.
Pharmacokinetics
Onset
Therapeutic effects typically observed within 2-3 weeks of continuous administration.
Excretion
Mainly excreted in urine as metabolites, with a small portion excreted unchanged.
Half life
Approximately 12-15 hours, supporting once-daily dosing.
Absorption
Well absorbed from the gastrointestinal tract; peak plasma concentrations reached in 6-8 hours due to modified-release.
Metabolism
Primarily hepatic metabolism via CYP450 enzymes (e.g., CYP3A4).
Side Effects
Contraindications
- Known hypersensitivity to the active substance or any excipients
- Severe hepatic impairment
- History of psychotic disorders
Drug Interactions
Metoclopramide
May antagonize the effects of Supadopa-TR.
Hypotensive agents
Increased risk of orthostatic hypotension.
Antipsychotics (e.g., haloperidol)
May reduce the efficacy of Supadopa-TR.
CYP3A4 inhibitors (e.g., ketoconazole)
May increase Supadopa-TR plasma levels.
Storage
Store below 30°C in a dry place, away from light and moisture. Keep out of reach of children.
Overdose
Symptoms may include nausea, vomiting, dizziness, orthostatic hypotension, hallucinations, and dyskinesia. Management involves symptomatic and supportive measures. Gastric lavage or activated charcoal may be considered shortly after ingestion.
Pregnancy & Lactation
Use during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is not known if Supadopa-TR is excreted in human milk; caution should be exercised when administering to a nursing mother.
Side Effects
Contraindications
- Known hypersensitivity to the active substance or any excipients
- Severe hepatic impairment
- History of psychotic disorders
Drug Interactions
Metoclopramide
May antagonize the effects of Supadopa-TR.
Hypotensive agents
Increased risk of orthostatic hypotension.
Antipsychotics (e.g., haloperidol)
May reduce the efficacy of Supadopa-TR.
CYP3A4 inhibitors (e.g., ketoconazole)
May increase Supadopa-TR plasma levels.
Storage
Store below 30°C in a dry place, away from light and moisture. Keep out of reach of children.
Overdose
Symptoms may include nausea, vomiting, dizziness, orthostatic hypotension, hallucinations, and dyskinesia. Management involves symptomatic and supportive measures. Gastric lavage or activated charcoal may be considered shortly after ingestion.
Pregnancy & Lactation
Use during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is not known if Supadopa-TR is excreted in human milk; caution should be exercised when administering to a nursing mother.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
36 months
Availability
Pharmacies, hospitals, specialized clinics
Approval Status
Approved by MediRegulatory Agency
Patent Status
Patent protected until 2040
Clinical Trials
Multiple Phase III clinical trials demonstrated significant improvement in UPDRS scores in Parkinson's patients. Data available upon request.
Lab Monitoring
- Routine blood pressure monitoring, especially during dose initiation and adjustment.
- Periodic assessment for psychiatric symptoms.
Doctor Notes
- Advise patients to report any impulse control issues immediately.
- Gradual dose titration is crucial to minimize side effects.
- Monitor for orthostatic hypotension, especially in elderly patients.
Patient Guidelines
- Take at the same time each day.
- Do not stop taking the medication abruptly.
- Report any unusual changes in behavior or mood to your doctor.
Missed Dose Advice
If a dose is missed, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose and resume your regular dosing schedule. Do not double the dose.
Driving Precautions
Supadopa-TR can cause somnolence and sudden onset of sleep. Patients should be advised not to drive or operate machinery if they experience these symptoms.
Lifestyle Advice
- Maintain a healthy diet and exercise routine.
- Avoid sudden changes in posture to reduce the risk of orthostatic hypotension.
- Limit alcohol consumption.
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine. Click a brand to search for detailed information.
Other Medicines in Supadopa-TR Brand
Other medicines available under the same brand name
